Balchem Corp

Lobbying Governance

AI Extracted Evidence Snippet Source

Our Board of Directors' (our "Board") Corporate Governance & Nominating ("CG&N") Committee – in accordance with its responsibility to oversee the company's activities and practices regarding ESG matters – reviews our sustainability-related practices and monitors the company's progress in this area. Each year, we assess our view of priority ESG subject areas through an annual risk assessment, recalibrating as necessary. [...] Ensuring strong oversight of our ESG program through our Corporate Social Responsibility ("CSR") Management Team, which is comprised of leadership from all company segments who are Director-level and above, as well as the Chairman, President and Chief Executive Officer, the Sustainability Steering Committee, and the Head of Sustainability [...] Reviewing progress with management (quarterly), an operating committee (semi-annually), and our Board (annually) [...] Balchem is utilizing technology to improve data and reporting through the use of a software tool. Incorporating this tool into the ESG process streamlines data collection, provides accountability over metrics, informs management of operational trends, and assists with goal-setting.

https://balchem.com/wp-content/uploads/2024/10/Balchem-2022-Sustainability-Report.pdf

The Governance Committee periodically, and at least annually, reviews Balchem's sustainability efforts, ESG strategy, initiatives, and policies. [...] Our Governance Committee, in connection with its responsibility for reviewing the Company's activities and practices regarding sustainability and ESG matters, maintains responsibility for oversight of our sustainability-related practices and monitors the Company's progress in this area. Periodically, and at least annually, our entire Board receives information on our sustainability and ESG efforts, with a focus on the Company's sustainability program, including performance against targets.

https://balchem.com/wp-content/uploads/2024/10/2024-Balchem-Proxy-Statement-Final.pdf